CN1079385A - The preparation method of liposome of anticancer medicine - Google Patents
The preparation method of liposome of anticancer medicine Download PDFInfo
- Publication number
- CN1079385A CN1079385A CN 92104309 CN92104309A CN1079385A CN 1079385 A CN1079385 A CN 1079385A CN 92104309 CN92104309 CN 92104309 CN 92104309 A CN92104309 A CN 92104309A CN 1079385 A CN1079385 A CN 1079385A
- Authority
- CN
- China
- Prior art keywords
- liposome
- preparation
- medicine
- spray drying
- oleogel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 210000000481 breast Anatomy 0.000 claims description 12
- 238000001694 spray drying Methods 0.000 claims description 12
- 239000003921 oil Substances 0.000 claims description 11
- 235000019198 oils Nutrition 0.000 claims description 11
- 239000012071 phase Substances 0.000 claims description 10
- 235000012000 cholesterol Nutrition 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- -1 L-Sarcolysinum Chemical compound 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 7
- 150000003904 phospholipids Chemical class 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 239000000787 lecithin Substances 0.000 claims description 6
- 235000010445 lecithin Nutrition 0.000 claims description 6
- 229940067606 lecithin Drugs 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- 210000002700 urine Anatomy 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 229920000609 methyl cellulose Polymers 0.000 claims description 5
- 239000001923 methylcellulose Substances 0.000 claims description 5
- 235000010981 methylcellulose Nutrition 0.000 claims description 5
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 125000000129 anionic group Chemical group 0.000 claims description 4
- 230000001804 emulsifying effect Effects 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000001488 sodium phosphate Substances 0.000 claims description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 4
- 239000000375 suspending agent Substances 0.000 claims description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 125000002091 cationic group Chemical group 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 claims description 2
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 claims description 2
- XIIAYQZJNBULGD-UHFFFAOYSA-N (5alpha)-cholestane Natural products C1CC2CCCCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 XIIAYQZJNBULGD-UHFFFAOYSA-N 0.000 claims description 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- UIMGHSAOLFTOBF-DPAQBDIFSA-N 3beta-Hydroxycholest-4-ene Chemical compound C1CC2=C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 UIMGHSAOLFTOBF-DPAQBDIFSA-N 0.000 claims description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- 229930195573 Amycin Natural products 0.000 claims description 2
- 229920000945 Amylopectin Polymers 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 claims description 2
- 229930192392 Mitomycin Natural products 0.000 claims description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 2
- 229940087168 alpha tocopherol Drugs 0.000 claims description 2
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims description 2
- 239000008346 aqueous phase Substances 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229960004630 chlorambucil Drugs 0.000 claims description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
- XIIAYQZJNBULGD-LDHZKLTISA-N cholestane Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 XIIAYQZJNBULGD-LDHZKLTISA-N 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 229940099578 hydrogenated soybean lecithin Drugs 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 2
- 229960000624 procarbazine Drugs 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 229940084106 spermaceti Drugs 0.000 claims description 2
- 239000012177 spermaceti Substances 0.000 claims description 2
- 150000007970 thio esters Chemical class 0.000 claims description 2
- 229960001196 thiotepa Drugs 0.000 claims description 2
- 229960000984 tocofersolan Drugs 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- 229960004528 vincristine Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
- 239000002076 α-tocopherol Substances 0.000 claims description 2
- 235000004835 α-tocopherol Nutrition 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229960005419 nitrogen Drugs 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 6
- 230000008685 targeting Effects 0.000 abstract description 4
- 238000002347 injection Methods 0.000 abstract description 3
- 239000007924 injection Substances 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000010287 polarization Effects 0.000 abstract description 2
- 238000012545 processing Methods 0.000 abstract description 2
- 230000008719 thickening Effects 0.000 abstract description 2
- 239000004531 microgranule Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000001267 polyvinylpyrrolidone Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Chemical class 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention is the preparation method of liposome of anticancer medicine, belongs to anti-cancer drug preparation technology.The present invention provides a class and is more suitable for leveling off to the preparation method of liposome of 100% (carcinoma entity direct injection) in targeting administration rate.Since this liposome interior, in, outer three layers all adopted the particular processing mode, the liposome that this law is made, be applicable to industrialized great production, simultaneously because this liposome has been taked means such as thickening, slow release, so during the direct administration of focus polarization good, unload leakage less, long action time.Compare the carcinoma entity to get pharmaceutical quantities accurate, controlled with the whole body administration, and local drug concentration height, curative effect height, instant effect, overall side effect are little.
Description
The invention belongs to anti-cancer drug preparation technology.
Cancer is worldwide generally acknowledged obstinate disease, existing tens of kinds more than of the cancer therapy drug that the approval of countries in the world government is used.Great majority all are whole body administration therapeutic methods such as oral, quiet notes, intracavity, intramuscular injection.This kind chemotherapy has the growth of inhibition and killing action to carcinoma really.But when carcinoma is suppressed or is partly killed, human normal tissue (hemopoietic system, detoxification system, genitourinary system etc.) also is subjected to wrecking greatly and injuring accordingly, cause at last human normal tissue never can resist the efficacy of a drug injury and be forced to drug withdrawal midway.Because carcinoma is organized and thoroughly do not killed, cause carcinoma recurrence in a period of time after the chemotherapy, transfer etc. to become certainty.Therefore people place on hope in the research of targeting good anticancer preparation liposome.The preparation method of existing liposome has membrane process, reverse evaporation, injection method, surfactant dilution method, squeezing and pressing method etc.But the liposome that conventional method is made (solution) all exists, and envelop rate is low, storage period is short, easily unload the problem that leakage waits, after freezing, the spray drying liposome dry product of gained also exist easy adhesion, moisture absorption, become sour rotten and redissolve with distilled water when using after the difficult problem such as press filtration homogenize of still needing.Simultaneously to say objectively liposome is not only carcinoma to be had bigger affinity, and is very high in abundances such as the abundant tissue of phagocyte such as liver, spleen, bone marrow, lungs yet.Therefore say that the targeting of liposome also is relative.Corresponding toxicities after the administration also is unavoidable.
Task of the present invention is to can be used under the prerequisite of whole body administration not discharging this liposome, provides a class and is more suitable in the liposome of the direct administration of carcinoma entity (targeting administration rate nearly 100%).
Liposome of anticancer medicine its preparation method of the present invention is: (mainly select for use those to have the Cytotoxic cancer therapy drug that can directly play a role in the carcinoma entity medicine; Can suppress the synthetic medicine of biological nucleic acid, it is close fixed etc. to dredge basic purine, hydroxyl urine, 5-fluorine urine as: 6-; The medicine that can change nucleic acid structure is as alkylating agent, Amboclorin, L-Sarcolysinum, cyclophosphamide, nitrous urine class, mitomycin, daunorubicin, procarbazine, amycin, bleomycin etc., can suppress mitotic medicine as vincaleucoblastine, vincristine etc. and cell cycle nonspecific agent (CCNSA) are as Thiotepa, nitrogen mustards etc.), its charged situation of complying with is divided into cationic medicine or anionic drug (does not have anionic drug in the above-mentioned medicine example, the close both sexes medicine that belongs to surely of 5-fluorine urine, but because of its facile hydrolysis in alkali liquor, so can only be with the characteristic of its cationic medicine, so the anionic example is omitted) two big classes, and add according to the classification of its medicine at aqueous phase and can make medicine dissolves (salify) in water acid buffer agent accordingly (as citric acid, succinic acid, acetic acid or oxalic acid etc.) or ealkaline buffer (as sodium carbonate, sodium bicarbonate, sodium phosphate, dibastic sodium phosphate etc.), oil phase (can be selected axunge for use, vegetable oil, the benzyl benzyl formate, ethyl oleate, chloroform etc.), the oil phase suspending agent (can be selected list for use, two, Aluminium Tristearate Micronized steriles etc.) matrix material (can be selected phosphatidylcholine for use, the lecithin phatidylcholine, the fabaceous lecithin phatidylcholine, the hydrogenated soybean lecithin phatidylcholine, two lauroyl lecithin phatidylcholines, dipalmitoyl phosphatidyl choline, distearoyl phosphatidylcholine, dimyristoyl phosphatidyl choline, two spermaceti phospholipid, the distearyl phosphatidyl glycerol, thioester, cholesterol, coprostenol, cholestane, Dihydrocholesterol, alpha-tocopherol etc.), the spray drying anticoagulant of high-viscosity polymer, entity injection slow releasing agent (can be selected sodium alginate for use, methylcellulose, carboxymethyl cellulose, polyvinylpyrrolidone, amylopectin and glue class etc.) above-mentioned former, adjuvant is standby after giving processing, medicine is dissolved in the internal layer water buffer, transfers PH4 or 9 standby.Phospholipid with suspending agent and 1/3 amount, cholesterol is dissolved in oil phase (oils and fats respectively, the chloroform mixed liquor) in, under agitation add above-mentioned pastille buffer in the oil phase then, carry out emulsifying and form w/o type Emulsion, again this W/O breast is removed most of organic solvent with gentle method, form spissated W/O Emulsion, this is concentrated the newborn fluidity that contains total amount 2/3 phospholipid and cholesterol that adds under the state that stirs transfer in PH6.5～7.5 aqueous solutions, form the compound breast of W/O/W type, after the homogenize, this breast is carried out spray drying simultaneously with high viscosity copolymer solution, get final product the liposome microgranule of surperficial formation one layer of polymeric thin film.
But the present invention is based on the direct administration of carcinoma entity owing to be on the basis of not discharging the whole body administration.Therefore have following characteristics: 1. to get pharmaceutical quantities accurate, controlled for the carcinoma entity, and local drug concentration height, curative effect height, instant effect, overall side effect are little; 2. this liposome has been taked means such as thickening, slow release, thus polarization is good, medicine from focus unload leakage less, long action time; 3. since this liposome interior, in, outer three layers all adopted special mode to handle.So the liposome that this law is made is not only applicable to industrialized great production, and solved that liposome (solution) preservation term is lacked, easily unloaded Lou, envelop rate is low, freezing, easy adhesion, moisture absorption that spraying, dry back gained dry product exist, become sour and redissolve with distilled water when using after need use a difficult problem such as particular device press filtration homogenize.
Prescription of the present invention, process example are: the 50mg vincristine sulfate is dissolved in the 60ml citric acid solution, and it is standby to transfer PH4.5 to constitute water.Neutral Oleum Glycines gel, 12g distearoylphosphatidylcholine phatidylcholine and cholesterol (1: 09 mole ratio) that 30g is contained 2% aluminum monostearate are dissolved in respectively in the 120g chloroform and constitute oil phase.Above-mentioned water is added in the oil phase, use the homogenizer homogenize, get w/o type Emulsion, this breast is evaporated 55～70% chloroforms under the decompression state below 50 ℃, get spissated w/o type Emulsion, this breast is contained transferring in the 600ml aqueous solution of PH7 through sodium bicarbonate of 24g distearoylphosphatidylcholine phatidylcholine and cholesterol (1: 0.7 mole ratio) in adding under the condition of stirring, be emulsified into W/O/W type multiple emulsion, then with this compound breast and the 600ml aqueous solution that contains the 6g methylcellulose evenly after spray drying immediately, get final product the liposome microgranule (about 130 grams) of surperficial formation one deck methylcellulose thin film packing promptly.
Annotate: during use, the redissolution of liposome microgranule can utilize methylcellulose easily molten in cold water, and insoluble characteristic in the water of temperature more than 45 ℃ can get homodisperse liposome suspension.
Claims (6)
1, the preparation method of liposome of anticancer medicine, the preparation that it is characterized in that this liposome is (to dredge basic purine as 6-by the medicine that will can directly play a role in the cancer entity, hydroxyl urine, the 5-fluorine is urinated close fixed, Amboclorin, L-Sarcolysinum, cyclophosphamide, nitrous urine class, mitomycin, daunorubicin, amycin, bleomycin, procarbazine, vincaleucoblastine, vincristine, Thiotepa, nitrogen mustards etc.) be dissolved in (internal layer water) in the corresponding buffer according to its charged situation and transfer the phospholipid of PH (making it to become water soluble salt) axunge (or oleogel) and 1/3 amount, constitute oil phase in the cholesterol solution chloroform, above-mentioned water is joined in the middle of the oil phase, carry out emulsifying and form w/o type Emulsion, this Emulsion is removed most of organic solvent with gentle method form spissated breast, this W/O is concentrated breast to add the PH that contains total amount 2/3 phospholipid and cholesterol and approximates in 7 the aqueous solution under the state that stirs, form the compound breast of W/O/W type after the emulsifying, this compound breast and high viscosity copolymer solution are carried out simultaneously operation such as spray drying and finish.
2, method for preparing lipidosome as claimed in claim 1, the buffer agent of aqueous phase should be selected according to the charged situation of its medicine in it is characterized in that, when medicine when being cationic, then need select for use with the acid buffer agent (as citric acid, succinic acid, acetic acid, oxalic acid etc.) of its composition water soluble salt, when medicine is anionic, then select ealkaline buffer (as sodium carbonate, sodium bicarbonate, sodium phosphate, dibastic sodium phosphate etc.) for use.
3, the preparation method of liposome as claimed in claim 1, it is characterized in that the double-deck molecular material of liposome can select phosphatidylcholine, lecithin phatidylcholine, fabaceous lecithin phatidylcholine, hydrogenated soybean lecithin phatidylcholine, two lauroyl lecithin phatidylcholines, dipalmitoyl phosphatidyl choline, distearoyl phosphatidylcholine, dimyristoyl phosphatidyl choline, two spermaceti phospholipid, distearyl phosphatidyl glycerol, thioester, cholesterol, coprostenol, cholestane, Dihydrocholesterol, alpha-tocopherol etc. for use, its total consumption is equivalent to 0.5～15% of spray drying proliposome solution; Inside and outside layer lipid ratio is about 1: 2; Wherein the ratio of phospholipid and cholesterol should be between 1: 0.2～1: 1, and the cholesterol level of internal layer lipid layer should be bigger than skin.
4, the preparation method of liposome as claimed in claim 1, the oil reservoir that it is characterized in that the compound breast of W/O/W type after the spray drying is the axunge or the oleogel of remaining trace only, so formed special liposome bilayer, axunge between this double-deck son or oleogel can effectively stop unloading leakage of water soluble drug.Wherein oleogel is made of suspending agent such as list, two, Aluminium Tristearate Micronized sterile etc. and oil phase such as vegetable oil, benzyl benzyl formate, ethyl oleate etc.The ratio of axunge or oleogel and liposome material should be between 0-500%, and the consumption of suspending agent should be 0.5%～5% of an oil phase in the oleogel.
5, the preparation method of liposome as claimed in claim 1, it is characterized in that to select extra large bath acid sodium, methylcellulose, carboxymethyl cellulose, each alkane ketone of polyethylene pyrrole, amylopectin and glue class etc. for use with the high-viscosity polymer of liposome simultaneous spray drying, its consumption should be looked the kind of polymer, and the back cancer entity that redissolves is injected required slow release degree and decided.Its spray drying process can will carry out spray drying method behind high-viscosity polymer liquid and the liposome mix homogeneously; Also can carry out spray drying method by different spray gun ejections with the chamber by two kinds of liquid.
6, the preparation method of liposome as claimed in claim 1, the foreign minister's aqueous solution that it is characterized in that containing 2/3 lipid should transfer to 7 with PH before emulsifying W/O/W breast about (slightly get final product on the contrary), so that the part medicine that spills when making preparation W/O/W newborn can return the internal layer water when spray drying in internal layer water PH.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 92104309 CN1079385A (en) | 1992-06-01 | 1992-06-01 | The preparation method of liposome of anticancer medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 92104309 CN1079385A (en) | 1992-06-01 | 1992-06-01 | The preparation method of liposome of anticancer medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1079385A true CN1079385A (en) | 1993-12-15 |
Family
ID=4940726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 92104309 Pending CN1079385A (en) | 1992-06-01 | 1992-06-01 | The preparation method of liposome of anticancer medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1079385A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1067552C (en) * | 1994-12-06 | 2001-06-27 | 大连医科大学 | Method for extracting lipid anti-cancer medicine from liver |
| CN1298327C (en) * | 2004-03-02 | 2007-02-07 | 南京康海药业有限公司 | Leurocristine sulfate liposome compositions, and its prepn. method |
| CN100356920C (en) * | 2004-12-27 | 2007-12-26 | 北京文卓医药生物制品技术开发有限公司 | Alkaloid liposome in vinca and production technique |
| CN100431605C (en) * | 2005-02-03 | 2008-11-12 | 山东蓝金生物工程有限公司 | Anticarcinogen composition |
| CN100562311C (en) * | 1999-11-05 | 2009-11-25 | 雷古隆公司 | Cisplatin micelles and methods of use |
| CN1923281B (en) * | 2005-08-30 | 2010-05-05 | 孔庆忠 | Anti-cancer slow release injection comprising plant alkaloid |
| CN1923171B (en) * | 2006-02-24 | 2010-05-19 | 济南康泉医药科技有限公司 | Compound recipe anti-cancer drugs slow release agent comprising anticancer antibiotics and synergist thereof |
| CN101513390B (en) * | 2009-03-24 | 2012-06-27 | 沈阳药科大学 | Hydrochloric acid boanmycin liposomes and preparation method thereof |
| CN101991537B (en) * | 2009-08-21 | 2012-10-24 | 华北制药集团制剂有限公司 | Compound fluorouracil liposome oral liquid and preparation method thereof |
| CN106166154A (en) * | 2016-04-29 | 2016-11-30 | 陈西敬 | A kind of compositions liposome of palmitoyl ascorbate and vincristine |
| CN115089549A (en) * | 2022-07-26 | 2022-09-23 | 河南中医药大学第一附属医院 | A kind of atomoxetine hydrochloride liposome, preparation and preparation method thereof |
-
1992
- 1992-06-01 CN CN 92104309 patent/CN1079385A/en active Pending
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1067552C (en) * | 1994-12-06 | 2001-06-27 | 大连医科大学 | Method for extracting lipid anti-cancer medicine from liver |
| CN100562311C (en) * | 1999-11-05 | 2009-11-25 | 雷古隆公司 | Cisplatin micelles and methods of use |
| CN1298327C (en) * | 2004-03-02 | 2007-02-07 | 南京康海药业有限公司 | Leurocristine sulfate liposome compositions, and its prepn. method |
| CN100356920C (en) * | 2004-12-27 | 2007-12-26 | 北京文卓医药生物制品技术开发有限公司 | Alkaloid liposome in vinca and production technique |
| CN100431605C (en) * | 2005-02-03 | 2008-11-12 | 山东蓝金生物工程有限公司 | Anticarcinogen composition |
| CN1923281B (en) * | 2005-08-30 | 2010-05-05 | 孔庆忠 | Anti-cancer slow release injection comprising plant alkaloid |
| CN1923171B (en) * | 2006-02-24 | 2010-05-19 | 济南康泉医药科技有限公司 | Compound recipe anti-cancer drugs slow release agent comprising anticancer antibiotics and synergist thereof |
| CN101513390B (en) * | 2009-03-24 | 2012-06-27 | 沈阳药科大学 | Hydrochloric acid boanmycin liposomes and preparation method thereof |
| CN101991537B (en) * | 2009-08-21 | 2012-10-24 | 华北制药集团制剂有限公司 | Compound fluorouracil liposome oral liquid and preparation method thereof |
| CN106166154A (en) * | 2016-04-29 | 2016-11-30 | 陈西敬 | A kind of compositions liposome of palmitoyl ascorbate and vincristine |
| CN115089549A (en) * | 2022-07-26 | 2022-09-23 | 河南中医药大学第一附属医院 | A kind of atomoxetine hydrochloride liposome, preparation and preparation method thereof |
| CN115089549B (en) * | 2022-07-26 | 2023-08-22 | 河南中医药大学第一附属医院 | A kind of atomoxetine hydrochloride liposome, preparation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69111821T2 (en) | ACTIVE SUBSTANCE DELIVERY VEHICLE SUSPENDED IN A NON-AQUE PERFLUORED CARRIER MEDIUM. | |
| US4897269A (en) | Administration of drugs with multiphase liposomal delivery system | |
| US4761288A (en) | Multiphase liposomal drug delivery system | |
| JP2848583B2 (en) | ER based on alpha-tocopherol | |
| DE3786555T2 (en) | INCREASED PRODUCTION OF HEMOGLOBIN Encapsulated With Liposomes. | |
| DE3439722C2 (en) | Osmotic capsule | |
| DE69837339T2 (en) | Change in drug loading in multivesicular liposomes | |
| DE69523602T2 (en) | AQUEOUS FOAMABLE COMPOSITION | |
| US4844904A (en) | Liposome composition | |
| DE69733966T2 (en) | SOLID LIPID COMPOSITIONS OF LIPOPHILIC COMPOUNDS FOR IMPROVED ORAL BIOVERABILITY | |
| DE2601207A1 (en) | PROCESS FOR MANUFACTURING A LIQUID PREPARATION WITH CONTROLLED DISPENSING CAPACITY | |
| CN1079385A (en) | The preparation method of liposome of anticancer medicine | |
| JPH07503254A (en) | Stable microfoam suspensions as reinforcing agents for ultrasonography | |
| CN1088777A (en) | The preparation method that is used for the chemotherapeutic preparation of directly administering to cancer nidus | |
| EP0177223B1 (en) | Pharmaceutical multi-phase composition | |
| DE69328794T2 (en) | CONTAINER WITH TRANSFUSION LIQUID AND PREPARED TRANSFUSION LIQUID | |
| CN101244039B (en) | Novel method for preparing indissoluble medicaments liposome preparations | |
| US20120177725A1 (en) | Preparations for the external application of antiseptic agents and/or agents promoting the healing of wounds | |
| DE20221486U1 (en) | Tamsulosin modified release tablets | |
| JP2001509477A (en) | Topical application of a combination of benzoyl peroxide and a second active ingredient | |
| EP4585208A1 (en) | Hyaluronic acid liposome assembly, and preparation method therefor and use thereof | |
| MXPA04012917A (en) | Liposomes containing biologically active compounds. | |
| DE2921852A1 (en) | LIPID LOWERING AGENT | |
| DE19810655A1 (en) | Pharmaceutical composition containing cyclosporin A suitable for topical administration for treating disorders of skin, mucosa and eyes | |
| MXPA01012170A (en) | Preparations for the application of anti-inflammatory agents. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |